GT Biopharma (GTBP)

Executive Summary

GT Biopharma is a publicly traded immuno-oncology company leveraging its proprietary TriKE® platform to develop novel biologic therapies for hematologic malignancies and solid tumors. Despite the termination of its lead candidate GTB-3550 in Phase 1/2 for high-risk myelodysplastic syndromes and acute myeloid leukemia, the company is advancing its pipeline with next-generation TriKE molecules designed to enhance natural killer cell engagement and tumor killing. With a small market capitalization of approximately $13.7 million, GT Biopharma operates in a high-risk, high-reward space, competing against larger players in NK cell therapy. Its near-term value hinges on clinical data from ongoing or planned trials, strategic partnerships, and capital raises to fund development.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1/2 trial for next-generation TriKE candidate (GTB-5550 or similar)40% success
• Q4 2026Announcement of strategic partnership or licensing deal for TriKE platform25% success
• Q3 2026FDA feedback or Orphan Drug Designation for any TriKE candidate20% success